Regulacje i polityka gospodarcza · 09/11/1998

NIH Seeks Licensees for Anti-Tac (Fv)-PE38 Immunotoxin for Leukemia and Lymphoma Treatment

The National Institutes of Health (NIH) is seeking companies to further develop and commercialize anti-Tac (Fv)-PE38, a potential treatment for refractory leukemia, lymphoma, and other hematologic malignancies. The immunotoxin, developed from a monoclonal antibody targeting the IL2 receptor, has shown promise in preclinical trials and is now poised to enter Phase II and III clinical trials.